A5000216315- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Gallbladder and Bile Duct Disorders
- Pancreatitis Pathology and Treatment
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Organ Transplantation Techniques and Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- Neuroblastoma Research and Treatments
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Screening and Detection
Memorial Sloan Kettering Cancer Center
2019-2025
Kaiser Permanente West Los Angeles Medical Center
2025
Cornell University
2021-2024
Weill Cornell Medicine
2024
Kettering University
2022-2024
Taiwan Power (Taiwan)
2018-2024
University Health Network
2012-2023
Sunnybrook Health Science Centre
2013-2023
St Joseph's Health Centre
2023
Health Sciences Centre
2013-2023
Among patients with metastatic pancreatic cancer, combination chemotherapy fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy safety of a modified FOLFIRINOX regimen as adjuvant therapy in resected cancer.
Singal, Amit G.; Llovet, Josep M.; Yarchoan, Mark; Mehta, Neil; Heimbach, Julie K.; Dawson, Laura A.; Jou, Janice H.; Kulik, Agopian, Vatche Marrero, Jorge Mendiratta-Lala, Mishal; Brown, Daniel B.; Rilling, William S.; Goyal, Lipika; Wei, Alice C.; Taddei, Tamar H. Author Information
Abstract Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here a phase I trial adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA real time from surgically resected PDAC tumours. After surgery, sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), cevumeran (a maximum 20 per patient) and...
<h3>Importance</h3> Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than those patients who are microsatellite-instability high (MSI-H). <h3>Objective</h3> To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) improved patient survival metastatic CRC. <h3>Design, Setting, Participants</h3> A randomized phase 2 study was conducted 27 centers across Canada...
Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment modified FOLFIRINOX vs gemcitabine in patients resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase was conducted 77 hospitals France Canada included aged 18 to 79 histologically confirmed adenocarcinoma who had undergone...
PURPOSE Previous studies suggest that besides anatomy (A: resectable, borderline resectable [BR], or locally advanced [LA]) also biologic (B: carbohydrate antigen 19-9 [CA 19-9]) and conditional (C: performance status) factors should be considered when staging patients with localized pancreatic ductal adenocarcinoma (PDAC). The prognostic value of the combined ABC has not been quantitatively validated. METHODS In this retrospective cohort study, we evaluated PDAC treated initial (modified)...
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present advanced disease and treated cytotoxic therapy. Genomic biomarkers prognostic of outcomes have been challenging to identify. Herein leveraging a cohort 2,336 spanning stages, we characterize the genomic clinical correlates in PDAC. We show that subtype wild-type tumors is associated early onset, distinct somatic germline features, significantly better overall...
Abstract Background Extended hepatectomy with resection of more than four segments is a high-risk operation, especially in patients hepatocellular carcinoma (HCC) associated chronic liver disease. This study evaluated the risk factors for morbidity and mortality following extended HCC. Methods Preoperative intraoperative variables 155 who underwent HCC were analysed to identify postoperative mortality. Results The overall rate was 55·5 per cent (n = 86). Most due ascites or pleural effusion....
Criteria for the selection of candidates liver transplantation in presence hepatocellular carcinoma (HCC) should accurately predict posttransplant recurrence while not excluding excessive numbers patients from candidacy. Existing criteria are challenged by limited accuracy radiological assessment. The total tumor volume (TTV) was calculated addition each individual tumor. A preliminary analysis carried out on HCC patient data Alberta Liver Transplant Program (52 patients) and then validated...
BACKGROUND The purpose of this study was to evaluate preoperative treatment with full‐dose gemcitabine, oxaliplatin, and radiation therapy (RT) in patients localized pancreatic cancer. METHODS Eligibility included confirmation adenocarcinoma, resectable or borderline disease, a performance status ≤2, adequate organ function. Treatment consisted two 28‐day cycles gemcitabine (1 g/m 2 over 30 minutes on days 1, 8, 15) oxaliplatin (85 mg/m 1 RT during cycle (30 Gray [Gy] 2‐Gy fractions)....
LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed the benefit of mFOLFIRINOX adjuvant setting. Methods: PRODIGE 24/CCTG PA.6 a phase III multicenter, randomized clinical trial. Pts aged 18-79 years histologically proven ductal adenocarcinomas, 21-84 days after R0 or R1 resection, WHO PS ≤1, adequate hematologic and renal function, no cardiac ischemia, were...
The aim of this study was to develop a prediction model for 10-year overall survival (OS) after resection colorectal liver metastasis (CRLM) based on patient, tumour and treatment characteristics.Consecutive patients complete CRLM were included from two centres (1992-2019). A providing OS probabilities developed using Cox regression analysis, including KRAS, BRAF histopathological growth patterns. Discrimination calibration assessed cross-validation. web-based calculator built predict...
Importance Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by presence liver metastases (LM). Objective To investigate association between LM and ICI advanced MSS Design, Setting, Participants In this secondary analysis Canadian Cancer Trials Group CO26 (CCTG CO.26) randomized clinical trial, patients with treatment-refractory cancer...
Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect patients undergoing liver resection for a cancer-related indication remains unclear.